Pfizer will provide XELJANZ (tofacitinib citrate) at no charge for the first 8 weeks of supply for standard induction therapy for ulcerative colitis, if the patient is eligible. Dispensing charges may apply from the nominated pharmacy, which is beyond Pfizer’s control.
After the first 8 weeks of supply, Pfizer will provide subsidised supply of XELJANZ with a patient copayment of $600 for every 4 weeks of supply. Copayment of this supply is payable to the nominated pharmacy at the time of dispensing and dispensing charges may apply from the nominated pharmacy, which is beyond Pfizer’s control.
In the event that personal information is shared with Pfizer, it will be collected and used in accordance with Pfizer Australia’s privacy policy available at www.pfizer.com.au/privacy.
Pfizer has the right to stop/alter this program at any time. Reasonable notice will be provided in advance of any changes to this program.